DNA methylation and repressive histones in the promoters of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, PD-L1, and galectin-9 genes in human colorectal cancer

被引：0
|
作者：
Varun Sasidharan Nair
Salman M. Toor
Rowaida Z. Taha
Hibah Shaath
Eyad Elkord
机构：
[1] Qatar Foundation,Cancer Research Center, Qatar Biomedical Research Institute, College of Science and Engineering, Hamad Bin Khalifa University
[2] Institute of Cancer Sciences,undefined
[3] University of Manchester,undefined
来源：
Clinical Epigenetics | 2018年 / 10卷
关键词：
Colorectal cancer; Immune checkpoints; PD-L1; Galectin-9; DNA methylation; Histone trimethylation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] DNA methylation and repressive histones in the promoters of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, PD-L1, and galectin-9 genes in human colorectal cancer
    Nair, Varun Sasidharan
    Toor, Salman M.
    Taha, Rowaida Z.
    Shaath, Hibah
    Elkord, Eyad
    CLINICAL EPIGENETICS, 2017, 10
  • [2] DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer
    Varun Sasidharan Nair
    Haytham El Salhat
    Rowaida Z. Taha
    Anne John
    Bassam R. Ali
    Eyad Elkord
    Clinical Epigenetics, 2018, 10
  • [3] DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer
    Nair, Varun Sasidharan
    El Salhat, Haytham
    Taha, Rowaida Z.
    John, Anne
    Ali, Bassam R.
    Elkord, Eyad
    CLINICAL EPIGENETICS, 2018, 10
  • [4] Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4+ T Cells
    Saleh, Reem
    Toor, Salman M.
    Khalaf, Sarah
    Elkord, Eyad
    VACCINES, 2019, 7 (04)
  • [5] CTLA4, PD-1, PD-L1, PD-L2, TIM-3, TIGIT, and LAG3 DNA Methylation Is Associated With BAP1-Aberrancy, Transcriptional Activity, and Overall Survival in Uveal Melanoma
    de Vos, Luka
    Cano, Tzaitel Maria Carrillo
    Zarbl, Romina
    Kluemper, Niklas
    Ralser, Damian Johannes
    Franzen, Alina
    Herr, Emmanuelle
    Gabrielpillai, Jennis
    Vogt, Timo Jakob
    Dietrich, Joern
    Strieth, Sebastian
    Landsberg, Jennifer
    Dietrich, Dimo
    JOURNAL OF IMMUNOTHERAPY, 2022, 45 (07) : 324 - 334
  • [6] Immune Co-inhibitory Receptors PD-1, CTLA-4, TIM-3, LAG-3, and TIGIT in Medullary Thyroid Cancers: A Large Cohort Study
    Shi, Xiao
    Li, Cui-Wei
    Tan, Li-Cheng
    Wen, Shi-Shuai
    Liao, Tian
    Zhang, Yan
    Chen, Tong-Zhen
    Ma, Ben
    Yu, Peng-Cheng
    Lu, Zhong-Wu
    Qu, Ning
    Wang, Yu
    Shi, Rong-Liang
    Wang, Yu-Long
    Ji, Qing-Hai
    Wei, Wen-Jun
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2021, 106 (01) : 120 - 132
  • [7] Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients
    Marcq, Elly
    De Waele, Jorrit
    Van Audenaerde, Jonas
    Lion, Eva
    Santermans, Eva
    Hens, Niel
    Pauwels, Patrick
    van Meerbeeck, Jan P.
    Smits, Evelien L. J.
    ONCOTARGET, 2017, 8 (52) : 89722 - 89735
  • [8] Targeting Tim-3 in Cancer With Resistance to PD-1/PD-L1 Blockade
    Tian, Tian
    Li, Zhaoming
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [9] The Search for an Interesting Partner to Combine with PD-L1 Blockade in Mesothelioma: Focus on TIM-3 and LAG-3
    Marcq, Elly
    Van Audenaerde, Jonas R. M.
    De Waele, Jorrit
    Merlin, Celine
    Pauwels, Patrick
    van Meerbeeck, Jan P.
    Fisher, Scott A.
    Smits, Evelien L. J.
    CANCERS, 2021, 13 (02) : 1 - 14
  • [10] CTLA-4, PD-1 and TIM-3 expression predominantly downregulated in MS patients
    Mohammadzadeh, Adel
    Rad, Isa Abdi
    Ahmadi-Salmasi, Babak
    JOURNAL OF NEUROIMMUNOLOGY, 2018, 323 : 105 - 108
12345